Nucleo Technologies INC

NucleoTech is a biotechnology company focused on advancing drug delivery systems to treat brain-related conditions. The company engineers proprietary carriers called BrainPortal, which are proteins designed to attach to therapeutic antibodies and oligonucleotides. By leveraging these carriers, NucleoTech enables therapeutics to cross the blood-brain barrier safely and non-invasively, addressing the physical barrier that prevents approximately 98% of drugs from reaching their targets in the brain. The company utilizes a direct in vivo screening platform that allows for the simultaneous testing of numerous carriers in living animals, significantly increasing the throughput and speed of discovery compared to conventional linear methods.

This technology is intended to overcome the significant limitations in treating complex neurological disorders, including neurodegeneration, brain cancers, and mental health conditions. By providing a scalable and efficient path for drug delivery, NucleoTech aims to advance its own internal CNS therapeutic pipeline and support pharma and biotech partners through licensing programs for its carrier portfolio. The company's approach removes the need for surgical intervention or complex drug reformulation, offering a pathway to bring previously blocked treatments to patients suffering from leading causes of disability and death worldwide.